Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death. Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity Provides an understanding of the mechanisms of cardiovascular toxicity of various therapies that may lead to the identification of novel targets to reduce vascular complications
This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs.
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. Emerging Risk Factors C. ... Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, ...
This edition addresses the cost effectiveness of interventions that educate and motivate patients to assume personal responsibility for long-term disease prevention.
Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: • Cardiac complications in patients receiving cancer therapy • The ...
This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients.
This work covers the pathophysiology of cancer, exploring the difficulty of optimal treatment due to the complexity and diversity of cancer types.
This book has four major parts. Part one will cover the basic metabolism of cancer cells, followed by a discussion of the heterogeneity of cancer metabolism in part two.
cardiac. toxicity. after. chemotherapy. and. radiation. therapy. in. breast. cancer. patients ... radiation therapy, cardiotoxicity INTRODUCTION Due to earlier detection and highly effective multi-modality treatments, cancer has become ...
This book intends to bring forward the recent development in toxicities from cancer treatment. It updates the possible mechanisms of cardiotoxicities of some anticancer agents and the suggested prevention and treatment strategies.
This book takes a holistic view of the treatment of cardio-oncology patients, from evaluating those at high risk of developing cardio-toxicity, guidance for monitoring and managing patients during therapy to cardiac care of cancer survivors ...